New Alzheimer’s disease findings to be shared at international conference
WHAT: The conference will review the most important and promising developments in Alzheimer's disease research. It encourages the exchange of ideas and techniques used to tackle one of the 21st century's most intractable problems. The aim is to accelerate the development of effective Alzheimer's disease treatments.
USC scientists will be available for embargoed interviews prior to the conference when some 1,100 worldwide leaders in Alzheimer's disease research will congregate in San Diego for a three-day event at the 9th annual conference for Clinical Trials on Alzheimer's Disease (CTAD).
Paul Aisen, director of the USC Alzheimer's Therapeutic Research Institute (ATRI), founded CTAD in 2008 along with Jacques Touchon, Bruno Vellas and Mike Weiner. Attendance at the conference will nearly triple this year compared to its inaugural year.
More than 70 researchers at USC are devoted to reimagining the way Alzheimer's disease is studied, diagnosed, prevented, treated and — perhaps one day — cured. These are the topics six USC scientists will speak about at CTAD:
- Phase 3 clinical trial that used Eli Lilly's drug solanezumab in people with mild dementia
- The search for Alzheimer's disease biomarkers in people with Down syndrome: a genetically predisposed population
- Stem cell use and regenerative therapeutics for Alzheimer's disease treatment
- Phase 3 clinical trial that used the drug LMTM on people with mild Alzheimer's disease to inhibit the accumulation of tau proteins
- Safety and efficacy of low-dose Ladostigil in patients with mild cognitive impairment
- The APOE gene and low levels of amyloid beta protein 42 (Abeta42) in cerebrospinal fluid may influence the activity of omega-3 fatty acids, which enhance synaptic plasticity, learning and memory
- Continued progress on Alzheimer's disease trial design
- Using algorithms to automatically classify adverse effects in clinical studies of Alzheimer's disease
- Using an interactive, open-source platform to monitor risk in Alzheimer's disease clinical trials
WHEN: Thursday, Dec. 8 — Saturday, Dec. 10
The presentation "EXPEDITION3: A phase 3 trial of solanezumab in mild dementia due to Alzheimer's disease" will take place from 6:15-7:45 p.m. PST on Thursday, Dec. 8 and will be streamed live at http://www.ctad-alzheimer.com/live-expedition-3-webcast.
WHERE: Marriott Marquis San Diego Marina
333 West Harbor Drive
San Diego, CA 92101
- Paul Aisen, director of the USC Alzheimer's Therapeutic Research Institute
- Michael Rafii, clinical director of the USC Alzheimer's Therapeutic Research Institute
- Lon Schneider, director of the USC California Alzheimer's Disease Center
- Hussein Yassine, assistant professor of medicine at the Keck School of Medicine of USC
- Gustavo Jimenez-Maggiora, director of informatics at the USC Alzheimer's Therapeutic Research Institute
- Rema Raman, director of biostatistics at the USC Alzheimer's Therapeutic Research Institute
RSVP for PRESS PASS: Call (213) 300-1381 or email [email protected]